Kensara Osama Adnan, El-Shemi Adel Galal, Mohamed Amr Mohamed, Refaat Bassem, Idris Shakir, Ahmad Jawwad
Department of Clinical Nutrition, Faculty of Applied Medical Sciences, Umm Al-Qura University, Holy Makkah, Saudi Arabia.
Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Holy Makkah, Saudi Arabia; Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Drug Des Devel Ther. 2016 Jul 11;10:2239-53. doi: 10.2147/DDDT.S109721. eCollection 2016.
Colorectal cancer (CRC) is one of the most prevalent cancers and has a high mortality rate. Insensitivity and the limited therapeutic efficacy of its standard chemotherapeutic drug, 5-fluorouracil (5-FU), represents an important challenge in CRC treatment. The robust antitumor properties of thymoquinone (TQ), the main bioactive constituent of Nigella sativa, have recently been demonstrated on different cancers. We investigated whether TQ could potentiate the chemopreventive effect of 5-FU to eradicate the early stages of CRC and elucidated its underlying mechanisms. An intermediate-term (15 weeks) model of colorectal tumorigenesis was induced in male Wistar rats by azoxymethane (AOM), and the animals were randomly and equally divided into five groups: control, AOM, AOM/5-FU, AOM/TQ, and AOM/5-FU/TQ. TQ (35 mg/kg/d; 3 d/wk) was given during the seventh and 15th weeks post-AOM injection, while 5-FU was given during the ninth and tenth weeks (12 mg/kg/d for 4 days; then 6 mg/kg every other day for another four doses). At week 15, the resected colons were subjected to macroscopic, histopathological, molecular, and immunohistochemical examinations. Interestingly, 5-FU/TQ combination therapy resulted in a more significant reduction on AOM-induced colorectal tumors and large aberrant crypts foci than treatment with the individual drugs. Mechanistically, 5-FU and TQ remarkably cooperated to repress the expression of procancerous Wnt, β-catenin, NF-κB, COX-2, iNOS, VEGF, and TBRAS and upregulate the expression of anti-tumorigenesis DKK-1, CDNK-1A, TGF-β1, TGF-βRII, Smad4, and GPx. Overall, our findings present the first report describing the in vivo enhancement effect of combined TQ and 5-FU against early stages of CRC; however, further studies are required to determine the value of this combination therapy in an advanced long-term model of CRC and also to realize its clinical potential.
结直肠癌(CRC)是最常见的癌症之一,死亡率很高。其标准化疗药物5-氟尿嘧啶(5-FU)的不敏感性和有限的治疗效果是CRC治疗中的一项重大挑战。黑种草籽的主要生物活性成分百里醌(TQ)对不同癌症具有强大的抗肿瘤特性,这一点最近已得到证实。我们研究了TQ是否能增强5-FU的化学预防作用以根除CRC的早期阶段,并阐明其潜在机制。通过给予雄性Wistar大鼠偶氮甲烷(AOM)诱导出中期(15周)的结直肠癌发生模型,然后将动物随机且平均分为五组:对照组、AOM组、AOM/5-FU组、AOM/TQ组和AOM/5-FU/TQ组。在注射AOM后的第7周和第15周给予TQ(35毫克/千克/天;每周3天),而在第9周和第10周给予5-FU(每天12毫克/千克,共4天;然后每隔一天6毫克/千克,再给药4次)。在第15周时,对切除的结肠进行大体、组织病理学、分子和免疫组化检查。有趣的是,与单独使用药物治疗相比,5-FU/TQ联合治疗对AOM诱导的结直肠癌肿瘤和大的异常隐窝病灶的减少更为显著。从机制上讲,5-FU和TQ显著协同作用,抑制癌前Wnt、β-连环蛋白、NF-κB、COX-2、iNOS、VEGF和TBRAS的表达,并上调抗肿瘤发生的DKK-1、CDNK-1A、TGF-β1、TGF-βRII、Smad4和GPx的表达。总体而言,我们的研究结果首次报道了TQ和5-FU联合对CRC早期阶段的体内增强作用;然而,需要进一步研究以确定这种联合治疗在晚期长期CRC模型中的价值,并实现其临床潜力。